Newark Delaware based Virion Therapeutics is raising $6,000,000.00 in New Debt Financing.
Newark, DE – According to filings with the U.S. Securities and Exchange Commission, Virion Therapeutics is raising $6,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Bernard Rudnick played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Virion Therapeutics
Virion Therapeutics is committed to developing treatments for cancer and chronic infections using targeted novel T-cell based immunotherapies that couple a checkpoint blockade with disease-specific antigenic stimulation. Our platform technologies, ChiVax and ChiVax-gD induce potent and sustained T cell-mediated immune responses against transformed or infected cells and have shown efficacy in a wide range of preclinical animal models including: animal models of fast and slow growing tumors, with viral or human cancer antigens, in young and older animals, and when inserted into failing adenovirus vaccine candidates.
To learn more about Virion Therapeutics, visit http://www.viriontx.com/
Contact:
Bernard Rudnick, Chief Executive Officer
800-841-9303
brudnick@viriontx.com
https://www.linkedin.com/in/bernie-rudnick-5334a815/
SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved